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Abstract: Gout recently passed rheumatoid arthritis to become the most common inflammatory 
arthritis in the United States (US). However, epidemiologic studies indicate that the quality of 
gout management is suboptimal owing to both patient and physician issues. Only three options 
for urate-lowering therapy are currently available in the US: allopurinol, probenecid, and recently, 
febuxostat. Probenecid is generally safe except for the occurrence of urolithiasis, but is only 
effective for the subset of patients with better kidney function. Allopurinol use is limited due 
to its side effects, potential toxicity of uncertain magnitude in patients with renal disease, and 
failure to achieve targeted serum urate levels. In part this failure may be due to the necessity 
for it to be titrated for optimal therapeutic effect. Febuxostat is a new medication that may 
offer several advantages and can be given as an alternative to allopurinol. We review the basic 
biology and clinical performance of febuxostat, and consider the potential utility of this agent 
in comparison to the older, better-established gout therapeutics.
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Introduction
The incidence of gout is on the rise, and gout recently passed rheumatoid arthritis 
to become the most common inflammatory arthritis in the United States, affecting 
some three million individuals.1,2 In gout, the presence of high levels of serum urate 
(hyperuricemia) results in the precipitation of monosodium urate crystals, which 
then activate the complement cascade, macrophages and neutrophils to stimulate epi-
sodic and often severe inflammatory responses.3,4 The deposition of large masses of 
sodium urate crystals in the synovium, surrounded by coronas of inflammatory cells 
(tophaceous gout), causes tissue and joint damage and chronic pain. Moreover, recent 
studies have identified associations between gout and multiple co-morbidities, includ-
ing hypertension, diabetes, obesity, and coronary artery disease, with some evidence 
that gout or hyperuricemia may contribute to these conditions.5–7
Management of gout generally requires the use of a combination of anti-inflammatory 
and urate-lowering agents, including colchicine, nonsteroidal anti-inflammatory drugs 
(NSAIDs) and glucocorticoids (anti-inflammatory), as well as probenecid and allopurinol 
(urate-lowering). While these urate-lowering agents are physiologically effective (with recom-
mendations from the European League Against Rheumatism suggesting that a target serum 
urate 6.0 mg/dL is optimal to reduce attacks8), studies indicate that the quality of gout 
management is typically poor, owing to both patient and physician issues.9 Moreover, the 
high rate of co-morbidities found in gout patients frequently translate into contraindications International Journal of Nephrology and Renovascular Disease 2010:3 
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to the currently available therapies.10 Two other agents may have 
limited use. Benzbromarone (an effective uricosuric) has been 
largely withdrawn from the market owing to hepatotoxicity but is 
still available in some European countries.11 Rasburicase (recom-
binant urate oxidase) degrades urate, but its cost, allergenicity 
and tendency to tachyphylaxis limit its effectiveness; it has been 
approved for tumor lysis syndrome but not gout.12 Accordingly, 
newer, better and safer medications are still needed.
Uric acid is an end-product of purine metabolism in 
humans and other mammalian species, and is the result of the 
step-wise actions of the enzyme xanthine oxidase/xanthine 
dehydrogenase, which converts the purine breakdown product 
hypoxanthine (via xanthine) to uric acid.13 Inhibition of xan-
thine oxidase/xanthine dehydrogenase by the purine analog 
allopurinol results in decreased serum uric acid levels and 
improved prognosis for gout. However, some individuals may 
not tolerate allopurinol owing to a potentially lethal hypersen-
sitivity syndrome.14 Since allopurinol and its active metabolite 
are excreted by the kidneys, some controversy exists as to the 
safety of allopurinol in patients with chronic kidney disease 
(CKD). Moreover, some patients fail to achieve sufficient 
urate lowering with the use of allopurinol. Febuxostat (also 
known as TEI-6720, TMX-67 and Uloric™; Takeda Pharma-
ceuticals, Deerfield, IL) is an orally-administered inhibitor 
of xanthine oxidase that was approved for the treatment of 
chronic hyperuricemia and gout in 2008 in Europe and in 
2009 in the US. Febuxostat has a number of biochemical and 
pharmacodynamic differences from allopurinol, suggesting 
that, in some patients at least, it may represent a better option 
for serum urate management. In this manuscript, we review 
the basic biology and clinical performance of febuxostat, and 
consider the potential utility of this agent in comparison to 
the older, better-established gout therapeutics.
Overview of pharmacology, mode 
of action, and pharmacokinetics 
of febuxostat
Basic pharmacology
Like allopurinol, febuxostat (2-(3-cyano-4-isobutoxyphenyl)-
4-methylthiazole-5-carboxylic acid; Figure 1) inhibits xanthine 
oxidase (XO), an enzyme with a molybdenum-containing active 
site, to reduce the production of uric acid from hypoxanthine. 
Activity of XO depends on the redox state of its catalytic cen-
ter molybdenum, complexed by a pterin compound to form 
the molybdenum-pterin cofactor. However, the mechanisms 
of action of these two XO inhibitors are not identical. Allo-
purinol is a purine analogue and is metabolized both by XO 
and by the phosphoribosyltransferases, hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT) and orotate phospho-
ribosyltransferase (OPRT), to form nucleotide analogues. 
Allopurinol exerts relatively weak competitive inhibition of 
the oxidized form of XO, which rapidly oxidizes allopurinol to 
oxypurinol. In turn, oxypurinol binds tightly to, and inhibits, 
the reduced form of XO, resulting in suicide inhibition of XO 
activity. In contrast, oxypurinol binds only weakly to the oxi-
dized form of XO, and is displaced from the reduced form of 
the enzyme during spontaneous re-oxidation of molybdenum, 
with subsequent XO re-activation.
In contrast to allopurinol, febuxostat is not a purine 
analogue. Febuxostat’s inhibition of XO is mediated by high-
affinity binding of febuxostat within the narrow XO molecular 
channel leading to the molybdenum-pterin active site. In bind-
ing to this channel, febuxostat blocks substrate access to the 
active site independent of the redox-state of the molybdenum 
cofactor. It exerts a potent mixed-type inhibition, inhibiting 
both the oxidized and reduced forms of the XO.15 Febuxostat 
does not inhibit other enzymes involved in purine and pyrimi-
dine metabolism, which are inhibited by allopurinol and its 
metabolites due to their structural similarity to purines.16
In both in vitro and in vivo animal studies, febuxostat 
inhibited XO more potently than allopurinol.17 In one study 
in chimpanzees (which resemble humans in lacking uri-
case and having higher purine metabolite levels and urate 
excretion rates), both allopurinol and febuxostat (each 
5 mg/kg/day orally), decreased serum urate levels after 24, 
48, and 72 hours of administration. However, febuxostat was 
more effective than allopurinol at lowering uric acid. Allo-
purinol decreased serum urate concentration by 28% (24 h), 
42% (48 h), and 45% (72 h), as compared with the respective 
values for febuxostat of 56%, 70%, and 74%.18
Febuxostat pharmacokinetics
Febuxostat’s pharmacokinetics and pharmacodynamics have 









Figure  Chemical structure of febuxostat (Uloric® package insert; Takeda Pharma-
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renal or hepatic impairment, and in both nonblinded and ran-
domized, placebo-controlled trials.19–22 Approximately 85% 
of febuxostat is absorbed after oral intake, with peak serum 
concentrations achieved after one hour in healthy subjects.21,23 
Increasing the administered dose, or administering multiple 
doses, affects neither time to peak concentration (tmax), nor 
tissue distribution of febuxostat.24 Maximum plasma con-
centration (Cmax) increases are dose-proportional over the 
10–240 mg dose range, and in the area under the plasma 
concentration-time curve (AUC) over the 10–120 mg range.19 
Febuxostat in the blood is highly bound to plasma proteins, 
mainly albumin (99%). At steady state, it has a low volume 
of distribution of about 0.7 L/kg, and a half life (t1/2) of eight 
hours.23,24 Elimination half-life (t1/2) values tended to increase 
with increasing doses and were longer after multiple doses 
compared with a single dose.19
Febuxostat is metabolized mainly by conjugation (via 
liver uridine diphosphate-glucuronosyltransferase (UGT) 
enzymes) into acylglucuronide metabolites (22%–44%), and 
to a lesser extent (2%–8%) to its active oxidative metabolites 
67M-1, 67M-2, and 67M-4 (via cytochrome P-450).21,25 
Approximately 25%–45% of the drug is excreted in the urine 
as the conjugate, and an additional 2%–8% of the dose is 
excreted as oxidative metabolites. Less than 5% of a febuxo-
stat dose is detected in the urine as unchanged drug.19,21
In otherwise healthy individuals, age and gender were 
found to have no significant effect on febuxostat’s pharmaco-
kinetics, pharmacodynamics, or safety after daily oral dosing 
with 80 mg. These data suggested that no dose adjustment 
should be necessary based on these parameters.24
Febuxostat and renal impairment
Since patients with gout often have varying degrees of CKD, 
several studies have examined the pharmacokinetics and phar-
macodynamics of febuxostat in the setting of renal impairment. 
In a phase I trial, Hoshide determined the AUC of unchanged 
febuxostat in the plasma of 15 patients, assigned to 3 equal 
groups according to their renal function.26 Normal renal func-
tion was defined as creatinine clearance (CrCl) 80 mL/min, 
mild renal impairment as CrCl 50–80 mL/min, and moderate 
renal impairment as CrCl 30–50 mL/min. Febuxostat was 
administered as a single dose of 20 mg orally within 30 minutes 
after breakfast. Although increased plasma AUC for unchanged 
febuxostat was observed in the moderately renally- impaired 
group (4005.26 ± 1467.4 ng ⋅ h/ml vs the groups with mild 
renal impairment (2338.62 ± 290.36 ng ⋅ h/ml) and normal 
function (2644.08 ± 593.04 ng ⋅ h/ml)), the difference was 
less than twofold. On this basis, the authors concluded that 
moderate renal dysfunction did not have a significant impact 
on febuxostat metabolism. Five mild adverse events (AEs) 
were reported: gastric ulcer, constipation, headache, nausea, 
and upper respiratory tract infection; of these, only nausea 
was considered to be possibly related to febuxostat. It was not 
specified how the AEs were distributed according to kidney 
function.26
A second, larger phase I trial to evaluate safety, pharma-
cokinetics and pharmacodynamics of febuxostat in subjects 
with renal impairment was conducted as a parallel-group, 
open-labeled, multiple-dose study in three study centers.21 
32 men and women aged between 26 and 76 years were 
divided into four groups based on CrCl assessed by 24-hour 
urine collection. Normal renal function was defined as 
CrCl  80 mL/min/1.73 m2 (n = 11), mild renal impairment 
as CrCl 50–80 mL/min/1.73 m2 (n = 6), moderate renal 
impairment as CrCl 30–49 mL/min/1.73 m2 (n = 7), and 
severe renal impairment as CrCl 10–29 mL/min/1.73 m2 
(n = 7). Febuxostat was administered in the 80 mg dose once 
daily at approximately 8:00 AM, for seven consecutive days 
after an overnight fast. Mean febuxostat AUC24,u (estimated 
as the product of the AUC and the fraction of unbound 
febuxostat in plasma) and terminal phase elimination half-
life (t1/2z) values tended to increase with increasing renal 
impairment, whereas mean febuxostat tmax and Cmax,u peak 
plasma concentration for unbound febuxostat (Cmax,u) values 
were similar in subjects with CKD and those with normal 
renal function. Regression analysis indicated a statistically 
significant (P  0.05) inverse linear relationship of CrCl 
and AUC24,u and t1/2z. The urinary excretion of unchanged 
and total (unchanged + conjugated) febuxostat was lower in 
groups with greater degrees of renal impairment.
Mean renal clearance for febuxostat in subjects with 
mild, moderate, and severe renal impairment was approxi-
mately 48%, 46%, and 77% lower than in those with normal 
renal function. Conversely, mean Cmax and AUC24 values for 
febuxostat active metabolites (67M-1, 67M-2, and 67M-4) 
were greater in subjects with renal impairment than in those 
with normal renal function. Regression analysis indicated 
significant linear relationship of Cmax and AUC24 values for 
67M-1, 67M-2, and 67M-4, except Cmax of 67M-1. Renal 
clearance of the metabolites was lower for subjects in the 
renal impairment groups. There were no reported deaths, 
serious adverse events (SAEs) or premature discontinu-
ations due to AEs during this study. The majority of AEs 
were mild or self-limiting, the most frequently reported 
being diarrhea, abdominal pain, headache and flushing. 
When analyzed according to renal function, the frequency International Journal of Nephrology and Renovascular Disease 2010:3 
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of AEs was comparable across groups, with a tendency to 
more headaches and flushing in the normal renal function 
group and diarrhea in the severe and moderate renal impair-
ment group. The mean percent decrease in serum uric acid 
between the normal and the impaired renal function groups 
was comparable. Although plasma exposure to febuxostat 
and its metabolites was significantly higher in the renal 
impairment groups, the authors suggested that since the drug 
was well-tolerated, dose adjustment for renal function did 
not appear to be necessary. Mean serum concentrations of 
xanthine did increase substantially compared with baseline 
after seven days, which could raise concerns for the potential 
of xanthine crystal formation. However, the concentrations of 
serum xanthine were substantially lower than the solubility 
limit of xanthine in the serum, while the urinary concentration 
of xanthine did not increase with renal impairment. Overall, 
the authors concluded that the 80 mg febuxostat dose does 
not require adjustment in CKD.21
Febuxostat and hepatic impairment
The effects of mild-to-moderate hepatic impairment on phar-
macokinetics, pharmacodynamics, and safety of febuxostat 
were studied in a phase I study.20 Subjects took 80 mg of 
oral febuxostat daily for seven days. There were no statisti-
cally significant differences in the plasma pharmacokinetic 
parameters for unbound febuxostat and its active metabolites 
among three groups: eight subjects with mild hepatic impair-
ment (Child-Pugh class A), eight subjects with moderate 
hepatic impairment (Child-Pugh class B), and 11 subjects 
with normal hepatic function. The percentage decrease in 
serum uric acid was lower in hepatic impairment groups 
(49% with mild liver disease and 48% with moderate liver 
disease) compared to the normal hepatic group (62%). This 
lower percentage decrease was not considered clinically 
significant. The safety and efficacy of febuxostat in severe 
hepatic impairment has not been studied. However, hepatic 
toxicity has not been reported in animal studies.
Febuxostat safety and tolerability
Toxic effects of allopurinol are most typically seen in the set-
ting of the allopurinol sensitivity syndrome, a rare but occa-
sionally life-threatening condition. It has been suggested that 
febuxostat, by virtue of its greater selectivity, its nonpurine 
structure and its lesser reliance on renal excretion, may have 
an improved safety profile when compared with allopurinol. 
While this has not been demonstrated in any head-to-head 
study, safety profiles to date do suggest that febuxostat is 
generally safe and well-tolerated.
In a multicenter, randomized, double-blind, placebo-controlled, 
phase III trial involving 153 patients, the safety profile of 
febuxostat in patients with gout was evaluated.27 Patients 
with serum creatinine 1.5 mg/dL (CrCl  50 mL/min) were 
excluded. Subjects received febuxostat 40 mg, 80 mg, and 
120 mg or placebo once daily for 28 days. There were no sig-
nificant differences between febuxostat and placebo groups 
with regard to treatment-related AEs, the majority of which 
were mild to moderate in severity and dose-independent. 
The most frequent side effects were diarrhea, abnormal liver 
function tests and abdominal pain. The only possible SAE 
was Guillain–Barré syndrome in one patient who was taking 
80 mg of febuxostat.
In FACT, a phase III, randomized, double-blind trial, 762 
patients were randomly assigned to febuxostat (80 or 120 mg) 
or allopurinol (300 mg once daily) for 52 weeks.28 Patients 
with serum creatinine 1.5 mg/dL (CrCl  50 mL/min) 
were excluded. Overall incidence of treatment-related AEs 
was similar in all three groups, and included abnormal liver-
function tests, diarrhea, headaches, joint-related signs and 
symptoms and musculoskeletal and connective-tissue signs 
and symptoms. Once again, most side effects were mild to 
moderate in severity. Discontinuation rates were significantly 
higher in the 120 mg febuxostat group, but were similar 
in 80 mg febuxostat group and allopurinol group. There 
were four deaths in the febuxostat groups and none in the 
allopurinol groups but the difference was not statistically 
significant (P = 0.31).
APEX (Allopurinol- and Placebo-Controlled, Efficacy 
Study of Febuxostat) a phase III, randomized, double-blind, 
placebo-controlled, parallel group trial included a small 
subset of subjects with moderate CKD (serum creatinine 
1.5 to 2 mg/dL).29 The trial included 1072 subjects who 
were randomized to once-daily febuxostat (80 mg, 120 mg, 
or 240 mg), allopurinol (100 mg or 300 mg based on renal 
function) or placebo, followed for 28 weeks. The frequency 
of adverse events was similar across the treatment groups. 
There were statistically increased incidences of diarrhea 
and dizziness in the febuxostat 240 mg group compared to 
the other treatment groups. There were no deaths reported 
during the study and the frequency of SAEs was similar in 
all groups. The most SAEs observed in all treatment groups 
were cardiovascular disorders (chest pain, coronary artery 
disease, myocardial infarction, and atrial fibrillation), in 
patients with a history of underlying cardiovascular disease 
or risk factors. These SAEs led to withdrawal in one patient 
taking 80 mg of febuxostat and two patients taking 120 mg 
of febuxostat. Overall nine patients withdraw from the study International Journal of Nephrology and Renovascular Disease 2010:3 
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due to serious AEs, one patient from the allopurinol group, 
and eight patients from the febuxostat treatment groups. 
However, only one subject experienced an SAE that was 
considered by the investigator to be related to the study 
drug. The subject reported a history of kidney stones and 
experienced a gradual increase in serum creatinine while 
receiving 240 mg of febuxostat from 1.1 mg/dL to 1.5 mg/dL 
on day 197. The serum creatinine returned to 1.3 mg/dL 
during treatment with febuxostat 120 mg in a subsequent 
extension trial.29 AEs leading to withdrawal occurred in 78 
subjects with similar frequency in all treatment groups. The 
most frequent AEs leading to withdrawal were abnormal liver 
function tests and diarrhea.
In EXCEL, an open-label extended comparative treatment 
trial, 1086 patients were assigned to febuxostat 80 mg or 
120 mg or allopurinol 300 mg or 100 mg and were followed 
for 40 months.30 A subset of patients with serum creatinine 
between 1.5 and 2 mg/dL were included. Patients were per-
mitted reassignment to achieve uric acid levels 6 mg/dL. 
Consequently, the duration of exposure was longer on 
febuxostat than on allopurinol. AEs were adjusted to duration 
of exposure; when adjusted, similar rates of AEs and SAEs, 
as well as rates of AEs resulting in premature discontinua-
tion, were reported. The most frequent SAEs were cardiac 
disorders which were equally represented in all treatment 
groups, when adjusted for duration of exposure. All 10 deaths 
reported (six were related to cardiovascular disease) occurred 
among subjects receiving febuxostat, with no dose- or time-
relation. There is no clear mechanism to explain these events. 
A need for further evaluation is suggested.30
In FOCUS (Febuxostat Open-label Clinical trial of 
Urate-lowering efficacy and Safety), the 28-day Phase II trial 
described above was extended into a five-year open-label 
trial.31 Of 153 subjects enrolled in the initial study, 116 were 
enrolled in the extension study. All subjects were initially 
started on 80 mg daily febuxostat for four weeks which was 
then adjusted to 40, 80, or 120 mg to maintain serum uric 
acid between 3 and 6 mg/dL, to respond to an adverse 
event, or at the discretion of the investigator. The majority of 
AEs were reported to be mild to moderate and investigators 
considered all SAEs unrelated to study drug. However, there 
was no placebo or comparative treatment group to assess the 
difference. Serious AEs were reported by 21/116 subjects; 
the most frequent SAE was atrial fibrillation and it was 
experienced by five subjects while on febuxostat 80 mg/day. 
Thirteen subjects discontinued treatment secondary to AEs. 
The most common AEs that caused withdrawal from the study 
were abnormal liver function tests, n = 3; cancers, n = 2; and 
two had increased serum creatinine. All three elevated liver 
enzymes and one increased creatinine were considered by 
investigators to be related to study drug.
Based on these and other observations, the prescribing 
information for febuxostat recommends monitoring liver 
function tests intermittently, and monitoring for signs and 
symptoms of myocardial infarction and stroke. Since febuxo-
stat (like allopurinol) may increase serum levels of agents 
that are otherwise metabolized by xanthine oxidase, and so 
induce secondary toxicity (potentially fatal aplasia), the use 
of febuxostat in patients taking azathioprine, as well as mer-
captopurine and theophylline, is contraindicated. No dosing 
adjustment is recommended in patients with mild to moderate 
renal impairment, mild to moderate hepatic impairment, or 
in geriatric patients (see Uloric package insert).
Efficacy studies
Febuxostat efficacy in patients  
with hyperuricemia and gout
The above-described phase II and phase III trials were also 
designed to assess various aspects of febuxostat’s efficacy. In 
the 28-day phase II trial, patients received colchicine for two 
weeks before, and two weeks after starting either febuxostat 
(40, 80, or 120 mg once daily) or placebo.27 The primary 
efficacy endpoint in this study was the proportion of subjects 
in each treatment group with serum uric acid levels 6.0. 
By the end of the study significantly greater proportions of 
patients in the febuxostat groups had achieved this endpoint 
relative to placebo, and the mean percentage reductions in 
serum uric acid from baseline were greater than placebo 
in all febuxostat groups, with the greatest reductions in 
patients receiving 120 mg/day of febuxostat (reduction of 
53%–59% in serum urate). Significantly greater proportions 
of patients in the febuxostat groups also achieved lower serum 
urate targets (4.0 and 3.0 mg/dL). Thus, febuxostat at 
all doses was superior to placebo at lowering serum urate 
levels. Perhaps not surprisingly, patients with the highest 
baseline levels of serum urate in each group were least likely 
to achieve the target urate in any of the therapy arms. In 
patients on colchicine, the incidence of gouty flares was not 
different among the four groups (range 8%–13%). However, 
in patients no longer on colchicine, the incidence of gouty 
flares was higher in the febuxostat 80 and 120 mg/day groups 
(40% and 42%, respectively) than in the placebo (34%) or 
febuxostat 40 mg/day (30%) groups, consistent with the 
established observation that urate lowering by any means 
acutely increases the risk for gout flare in the absence of 
inflammatory prophylaxis.International Journal of Nephrology and Renovascular Disease 2010:3 
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In the FACT trial (febuxostat 80 or 120 mg/day vs allo-
purinol for 52 weeks), patients received prophylaxis against 
gout flares for the first eight weeks of the study, using either 
colchicine or naproxen.32 The primary efficacy endpoint 
was a serum urate concentration 6.0 mg/dL at each of the 
last three monthly visits, with secondary endpoints includ-
ing proportion of subjects with a serum urate 6.0 mg/dL 
at each visit, and the percentage reduction in serum urate 
from baseline at each visit. Clinical endpoints included 
reduction of incidence in gout flares and (for patients with 
tophi) reduction in tophus number and area. The primary 
end point was achieved by 53% of patients taking 80 mg 
febuxostat, 62% taking 120 mg, and only 21% taking allo-
purinol. Secondary endpoints of urate lowering were also 
achieved more frequently in the febuxostat groups, and (in 
a post hoc analysis) patients in both febuxostat groups also 
achieved lower targets of serum urate (5.0 and 4.0 mg/dL) 
more frequently than those in the allopurinol group. During 
the initial induction phase, the incidence of gouty attacks 
was significantly greater in the febuxostat 120 mg group 
than in the febuxostat 80 mg or allopurinol 300 mg group, 
but these differences were not observed during the remainder 
of the study. All three groups experienced a transient surge 
in gout flares, lasting until approximately week 20, upon 
withdrawal of the initial inflammatory prophylaxis. In spite 
of its superiority at lowering serum urate levels, febuxostat 
showed a trend, but no statistically significant superiority to 
allopurinol in preventing gout flares by 52 weeks. Patients 
taking febuxostat also demonstrated a nonstatistically sig-
nificant trend toward improved reduction in tophus surface 
area (83% reduction for febuxostat 80 mg and 66% reduction 
for febuxostat 120 mg, vs 50% reduction for patients taking 
allopurinol 300 mg). Overall, the authors concluded that 
febuxostat at all doses was superior to allopurinol 300 mg 
for urate lowering.
The primary efficacy end point of the APEX trial (febuxo-
stat 80, 120, and 240 mgs vs allopurinol 300 mg; for patients 
with serum creatinine level 1.5–2.0 mg/dL, 100 mg daily 
vs placebo) was the proportion of subjects with the last 
three monthly serum urate levels 6.0 mg/dL.29 Secondary 
end points were similar to those in FACT and included 
proportion of subjects with a serum urate 6.0 mg/dL at 
each visit, percent reduction in serum urate, proportion of 
subjects requiring treatment for a gout flare, and reduction 
in size and number of tophi. A significantly greater percent-
age of patients receiving any dose of febuxostat achieved 
the primary end point vs allopurinol, with 50%–70% of 
the febuxostat, 20%–30% of the allopurinol, and none of 
the placebo subjects achieving target levels. By the time of 
the last visit, 76% of febuxostat 80 mg/day subjects, 87% 
of febuxostat 120 mg/day subjects, and 94% of febuxostat 
120 mg/day patients had achieved serum urate levels 6.0, 
compared with 41% of the allopurinol subjects and 1% of 
the placebo group. Febuxostat was also more effective than 
both allopurinol and placebo in urate lowering in patients with 
high (10 mg/dL) baseline urate levels. As in the FACT trial, 
a greater proportion of patients in the higher dose (120 and 
240 mg) febuxostat groups experienced gouty flares during 
the initiation of the study, whereas no differences between the 
febuxostat and allopurinol groups were seen at longer time 
points. Among patients with tophi, treatment with febuxostat 
120 mg, but, not with other doses of either febuxostat or 
allopurinol, resulted in a statistically significant decrease in 
the number of tophi versus placebo at week 28. In subjects 
with renal impairment, the use of allopurinol 100 mg/day 
was not sufficient to achieve urate lowering.
The EXCEL trial was longer than any of the previous tri-
als, and represented a combined extension study of patients 
who had previously enrolled in either FACT or APEX. 1280 
patients were screened, and 1086 were enrolled and followed 
for up to 40 months, permitting assessment of long-term 
urate lowering on the incidence of gouty flares and the pres-
ence of tophi. Although the protocol was changed slightly 
after initiation, patients received either febuxostat (80 mg or 
120 mg/day) or allopurinol (300 mg/day; 100 mg for a small 
number of patients with renal impairment); some provision 
was permitted for changing medications for lack of efficacy. 
The primary efficacy endpoint was the proportion of sub-
jects with serum urate 6.0 mg/dL at each visit; secondary 
endpoints included reduction of incidence of gout flares, 
percentage reduction in number of tophi, and reduction in 
size or disappearance of an index tophus. In the first months 
of treatment, patients in the febuxostat 80 mg and 120 mg 
groups achieved target urate lowering more often than those 
in the allopurinol group. For example, after one month, 81% 
of the febuxostat 80 mg subjects, and 87% of the febuxostat 
120 mg subjects achieved serum urate 6.0 mg/dL, versus 
49% of the allopurinol 300 mg subjects. Beyond 20 months, 
all three groups achieved a similar frequency of urate lower-
ing, a phenomenon the authors ascribed to the shift of some 
allopurinol patients, for whom the drug had been inadequate, 
into the febuxostat groups. Regarding gout flares, by the end 
of the study all three groups achieved a similar reduction in 
gout flares, but again, the shift of some allopurinol “failures” 
to the febuxostat groups made it impossible to compare the 
relative efficacies of the drugs overall at these late time points. International Journal of Nephrology and Renovascular Disease 2010:3 
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As in prior studies, treatment in all three urate-lowering 
arms led to an increase in gouty attacks during the initial 
urate-lowering phase (4–6 months), with the higher dose of 
febuxostat (120 mg) producing the greatest increase in gout 
flares. Patients in all three groups demonstrated reduction 
in size and number of tophi, consistent with the long-term 
lowering of uric acid to similar degrees.
Finally, the open-label FOCUS trial (febuxostat 80 mg/day, 
with an option to adjust dosing in an initial phase to 40 
or 120 mg) had no control group, and took as its primary 
end point the proportion of subjects achieving serum urate 
6.0 mg/dL.31 Secondary endpoints included percent reduc-
tion from baseline serum urate, proportion of subjects achiev-
ing a urate of 5.0 and 4.0 mg/dL, the proportion of subjects 
who required treatment for gout flare and the proportion of 
subjects with resolution of tophi. Most patients completed 
the study on 80 mg daily, though a smaller number remained 
on 40 mg or 120 mg after the initial adjustment period. By 
the end of the study period, between 80 and 100% of patients 
had achieved the target urate value. Despite the generally 
fast effect of febuxostat, some patients required as long as 
3–4 years to achieve their lowest urate levels. Overall, the 
percentage of patients experiencing gouty flares initially 
increased, then gradually declined, approaching zero by the 
end of the study period. Approximately 70%–80% of patients 
experienced complete resolution of an index tophus. The rate 
of tophus disappearance was relatively linear until week 208, 
after which no additional tophus resolution was seen.
Collectively, these trials attest to the ability of febuxostat 
to rapidly reduce serum urate. In this regard, febuxostat at all 
doses appeared to be more effective than allopurinol 300 mg (or 
100 mg in patients with mild to moderate renal failure). How-
ever, in this regard it is worth noting that the FDA-approved 
dose range for allopurinol is up to 800 mg, and no study has 
compared febuxostat with higher- or sliding-dose allopurinol. 
The ability of febuxostat to lower urate is clearly reflected in its 
ability to eventually reduce gouty flares, although its relative 
benefit in this regard vs allopurinol (300 mg or any other dose) 
is not clearly established by the studies to date. Finally, these 
studies indicate that successful long-term reduction of serum 
urate, whether by febuxostat or allopurinol, eventually results 
in the potential for almost complete abrogation of gout flares 
as well as the resolution of previously established tophi.
Febuxostat and renal stones
Hyperuricosuria is a risk factor for formation of both uric 
acid and calcium stones. However, lowering uric acid excre-
tion is not the preventive strategy of choice for uric acid 
stones and has an adjunctive role for prevention of calcium 
stones. Risk factors for uric acid stones are low urine volume, 
hyperuricosuria, and most importantly, low urine pH.33 The 
preeminent effect of low urine pH is demonstrated by the 
frequent occurrence of uric acid stones in patients who do 
not have hyperuricosuria but do have an unvaryingly low 
urine pH, usually of 5.5 or less. The pathophysiology of the 
persistently low urine pH often seen in patients with gout now 
appears to be caused by insulin resistance, and accounts for 
a higher prevalence of uric acid stones in patients with the 
metabolic syndrome.34
While low urine pH and hyperuricosuria contribute to 
uric acid stones, in the absence of an acid urine, patients so 
affected are unlikely to have uric acid stones, and may have 
calcium stones. If hyperuricosuria is present in uric acid stone 
formers, treatment with urate-lowering therapy is unlikely to 
be effective in stone prevention if alkalinization of the urine 
is not achieved. Since even normal or low uric acid excretion 
may be associated with uric acid stone formation in an acid 
urine, as occurs in patients with ileostomies, urate-lowering 
therapy without alkalinization is unlikely to lower urine super-
saturation to a value low enough to cause uric acid crystals to 
dissolve. Therefore the role of both allopurinol and febuxostat 
in uric acid stone formers is likely to be minimal. The drugs 
might best be applied in such patients who have difficulties 
achieving urine pH of 6.5 at least once a day or who persist in 
forming uric acid stones despite adequate alkalinization.
Hyperuricosuria may be a contributing risk factor for 
calcium stones. The evidence however is not conclusive as 
there is a discrepancy between the epidemiologic data and 
the results of a single randomized controlled trial. In three 
prospectively followed, well-studied cohorts of both men 
and women, increasing 24-hour uric acid excretion was not 
a predictor of a greater risk for stone incidence as compared 
with controls without stones.35 In fact, in younger women and 
men, uric acid excretion was inversely associated with stone 
incidence. These data are limited by not having information 
about stone composition, but the expectation would be that 
most stones were calcium.
The epidemiologic data contrast with the results of a study 
that demonstrated that allopurinol reduced the incidence of 
calcium stones.36 Patients with stones composed of more 
than 79% calcium oxalate, hyperuricosuria (800 mg/dL 
in men, 750 mg/dL in women) and normocalciuria 
(300 mg/dL in men, 250 mg/dL in women) were eligible. 
Results for 60 patients were analyzed after randomization to 
either allopurinol 100 mg three times a day, or placebo and 
up to three years of therapy. New stone events occurred in International Journal of Nephrology and Renovascular Disease 2010:3 
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18 subjects receiving placebo and nine receiving allopurinol, 
a significant difference. The allopurinol group also had a 
significantly longer time before recurrence. Since allopurinol 
is not known to have any effect on calcium metabolism or 
urine chemistry other than lowering of uric acid excretion, 
the effect to reduce calcium stone formation is attributed to 
“salting out”, the ability of uric acid to cause precipitation 
of dissolved calcium oxalate from solution.37
These interesting results suggest that febuxostat could 
have a role in preventing kidney stones. Its place for preven-
tion of calcium stones could be determined by comparing its 
relative efficacy in lowering uric acid excretion in patients 
with calcium stones and if followed for long enough, its abil-
ity to prevent new stone events could be measured. Whether 
it is useful to lower uric acid excretion in patients with other 
abnormalities of urine chemistry, such as hypercalciuria or 
hypocitraturia, excluded from the allopurinol trial described 
above, would also be important to determine.
Febuxostat from the patient 
perspective
For gout patients who require urate lowering, only three 
options are currently available in the US: allopurinol, pro-
benecid, and now febuxostat. In contrast to allopurinol and 
febuxostat, probenecid works to stimulate renal uric acid 
excretion by blocking renal tubular resorption of urate via 
inhibition of the URAT1 organic ion transporter. Probenecid 
is most effective in patients with normal glomerular filtration 
rates (GFR) who, as a result of intrinsic renal tubular defects, 
under-excrete uric acid. Probenecid has limited or no effect 
in patients with reduced GFR, whether due to chronic or 
acute kidney disease. Moreover, since probenecid increases 
uric acid delivery to the collecting system, it may raise the 
risk of calcium acid renal stones as described above. Con-
sequently, even patients who do not have a history of renal 
stones require consumption of copious amounts of water or 
beverages daily to reduce stone risk. Given a history of uric 
acid stones, potassium or sodium citrate should be prescribed 
to alkalinize the urine. The relatively short half-life of proben-
ecid requires that it be administered thrice daily. Therefore, 
although probenecid is a generally safe and effective drug, 
even the subset of patients for whom probenecid is a good 
choice tend to prefer an easier alternative.
For more than five decades, allopurinol has been that 
alternative. Most patients take allopurinol on a once-daily 
dosing schedule, and beyond anti-inflammatory prophylaxis, 
no ancillary medications are needed. In the majority of 
patients, allopurinol has little or no toxicity. However, a small 
number of patients develop the allopurinol hypersensitivity 
syndrome, which can involve liver, renal and marrow toxicity. 
For those patients – or for patients who develop a rash on allo-
purinol, since a rash may be a harbinger of the hypersensitiv-
ity syndrome – there are few if any good alternatives. Another 
drawback of allopurinol is the fact that many patients taking 
allopurinol fail to achieve targeted serum urate levels. In a 
spot study that we recently conducted, the mean serum uric 
acid level in patients receiving allopurinol from the primary 
care clinics of a large veterans hospital was 6.9 mg/dL, nearly 
a point above the recommended maximum target serum urate 
level.38 The reasons for this failure of allopurinol are not fully 
elucidated, but most likely relate to the relatively limited 
efficacy of the 300 mg dose; the failure of many physicians to 
appreciate that allopurinol should be titrated not to a specific 
dose, but to a serum urate target level; and the fact that in “real 
world medicine,” the time required to titrate a patient to the 
necessary dose can sometimes be quite extended and provide 
ample opportunity for compliance failure. The superiority of 
febuxostat to allopurinol 300 mg should not be construed 
as superiority to allopurinol overall, since allopurinol is US 
Food and Drug Administration (FDA)-approved at doses up 
to 800 mg/day. On the other hand, patients who need such 
high levels of allopurinol will frequently take a long time to 
achieve the target dose, and will typically need to advance 
to twice-daily dosing.
For patients with CKD, controversy exists as to the safety 
of allopurinol, with some studies suggesting an increase 
in toxicity and others suggesting none, particularly when 
allopurinol dosing is started low and adjusted specifically 
to target urate (ie, to avoid prescribing more than is actually 
necessary). In general, the community consensus would 
appear to be moving to the latter point of view.39–41 It is 
likely, therefore, that adequate results can be achieved with 
allopurinol in renal patients, even those needing a higher 
dose; however, the safety profiles of such doses has not been 
well established. Moreover, the use of allopurinol in patients 
with renal insufficiency may require a slower titration period 
and more monitoring, with its attendant inconvenience to 
the patient. The fact that febuxostat is approved for indi-
viduals with mild to moderate renal insufficiency, defined 
as CrCl  30 mL/min, and does not need dosing adjust-
ment in these individuals, makes for a simpler management 
algorithm for patients and physicians alike. It is important 
to note that all long term follow up studies excluded patients 
with creatinine higher than 2 mg/dL. In addition, although 
elevation of creatinine has been reported as a very rare AE, 
monitoring of kidney function is prudent.International Journal of Nephrology and Renovascular Disease 2010:3 
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From the patient’s point of view, therefore, febuxostat 
may offer several advantages. It can be given as an alterna-
tive to allopurinol for those patients who have allopurinol 
hypersensitivity; it will typically provide a more rapid time-
to-target serum urate than allopurinol; its dosing is always 
once a day, and simplified by the fact that only two dose levels 
(40 mg and 80 mg) are available (and generally needed). 
When compared with the 300 mg dose of allopurinol at 
least, febuxostat works better and faster to lower urate, and 
appears to be a better agent for reducing tophi. Patients who 
are less motivated to work with their physicians, have mild 
to moderate CKD, or who need relief more quickly, may 
therefore benefit from the simplicity of febuxostat. On the 
other hand, it must be recognized that patients starting on 
febuxostat are more likely to experience a temporary increase 
in gouty flares than those starting allopurinol; the importance 
of rigorous anti-inflammatory prophylaxis therefore deserves 
emphasis. Given a possible slight increase in cardiac events, 
patients with cardiovascular disease should probably discuss 
this issue with their physicians. Moreover, to the extent that 
patients are also consumers, the relative costs of febuxostat 
vs generic allopurinol (US$161.40 vs US$14.70 for 30 days) 
will also warrant consideration.42
Conclusions
For more than 50 years, clinicians have treated gout without 
recourse to any new medications. Although the previously 
available drugs could be rendered effective in most patients, 
achieving an appropriate level of gout control has often 
been a long, slow affair, and many patients never achieved a 
desirable level of control. Given the limited alternatives, little 
attention was paid to the possible toxicities of available gout 
therapies, particularly in view of the fact that many patients 
harbored comorbidities that represent contraindications to 
treatment. Viewed in this light, febuxostat is a welcome 
alternative. At the very least, febuxostat use will be war-
ranted in patients who require urate lowering but cannot 
tolerate allopurinol. The simplicity of febuxostat dosing, 
together with its established efficacy, may lead to its wider 
use, particularly among physicians with limited capacity to 
use probenecid or titrate allopurinol over time. With several 
other gout drugs currently in the pipeline,43–45 febuxostat 
may represent the first milestone in a new era of improved 
gout management.
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